3,70 €
0,75 % heute
L&S, 6. Oktober, 17:58 Uhr
ISIN
CA03879J1003
Symbol
ABUS
Berichte

Arbutus Biopharma Corporation Aktie News

Positiv
The Motley Fool
2 Monate alt
Arbutus (ABUS) Q2 Revenue Surges 529%
Neutral
GlobeNewsWire
2 Monate alt
Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran
Neutral
GlobeNewsWire
3 Monate alt
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China
Neutral
GlobeNewsWire
5 Monate alt
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no  interferon
Neutral
GlobeNewsWire
5 Monate alt
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER...
Neutral
GlobeNewsWire
6 Monate alt
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of t...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen